advertisement
PURPOSE: To determine the effectiveness and safety of brimonidine when used in combination with one or more glaucoma medications in patients with glaucoma or ocular hypertension. METHODS: Post hoc analysis of a multicenter, two-month, open-label, prospective, clinical trial in which 2335 patients received brimonidine as monotherapy, replacement therapy, or combination therapy. Patients who received brimonidine as combination therapy (n = 554) were examined in the current analysis. Efficacy was determined by the reduction in intraocular pressure (IOP) from baseline before the addition of brimonidine. Safety and tolerability parameters included adverse events and quality-of-life measures (e.g., ocular comfort, energy level, breathing ability, night vision). RESULTS: Addition of brimonidine to pre-existing regimens resulted in an overall mean additional reduction in IOP of 17.9% (4.26 mmHg) at month 2 (p < 0.001). Significant additional IOP lowering was provided by brimonidine in combination with each pre-existing regimen evaluated (p
Dr D.A. Lee, Department of Ophthalmology, Pennsylvania State University, Milton S. Hershey Medical Center, PO Box 850, Hershey, PA 17033-0850, USA. dalee@psu.edu
11.3.3 Apraclonidine, brimonidine (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)